Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Tocilizumab for the Treatment of Progressive or Recurrent Pediatric Adamantinomatous Craniopharyngioma

Trial Status: active

This phase II trial tests how well tocilizumab works in treating adamantinomatous craniopharyngioma that is growing, spreading and getting worse (progressive) or that has come back after a period of improvement (recurrent). Tocilizumab is a monoclonal antibody that binds to receptors for a protein called interleukin-6. This may help lower the body’s immune response and reduce inflammation and may also slow or stop tumor cell growth.